Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UW Hindbrain Malformation Research Program, |
RCV000201760 | SCV000256268 | pathogenic | Joubert syndrome 3 | 2015-02-23 | criteria provided, single submitter | research | |
Institute of Human Genetics, |
RCV002287391 | SCV002577938 | pathogenic | See cases | 2021-12-20 | criteria provided, single submitter | clinical testing | ACMG categories: PVS1,PM2,PP5 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003330575 | SCV004037959 | pathogenic | Joubert syndrome and related disorders | 2023-08-17 | criteria provided, single submitter | clinical testing | Variant summary: AHI1 c.736A>T (p.Lys246X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Variants downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 6.3e-06 in 159114 control chromosomes (gnomAD). c.736A>T has been reported in the literature in at-least one individual affected with Joubert Syndrome And Related Disorders (example: Fleming_2017). The following publication has been ascertained in the context of this evaluation (PMID: 29146704). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Fulgent Genetics, |
RCV000201760 | SCV005666354 | pathogenic | Joubert syndrome 3 | 2024-03-07 | criteria provided, single submitter | clinical testing |